Long-term follow-up data from the Phase I ANTLER trial showed that Caribou Biosciences’ investigational allogeneic CAR-T cell therapy CB-010 safely induced high rates of treatment response in patients with relapsed or refractory B cell non-Hodgkin lymphoma, the company announced Thursday.